Welcome to our dedicated page for Biocardia SEC filings (Ticker: BCDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BCDAW SEC filings page on Stock Titan provides access to public regulatory documents associated with BioCardia, Inc. and securities linked to the BCDAW symbol. BioCardia describes itself as a clinical-stage regenerative medicine company focused on cellular and cell-directed therapeutics for cardiovascular and pulmonary diseases, and its filings offer detailed insight into these activities.
Through current reports on Form 8-K, BioCardia has disclosed material events such as clinical and regulatory milestones for the CardiAMP Cell Therapy System and the Helix Transendocardial Delivery Catheter, including consultations with Japan’s Pharmaceuticals and Medical Devices Agency and pivotal Phase 3 trial enrollment for ischemic heart failure. Other 8-K filings describe an exclusive development and commercialization agreement with CART-Tech B.V. for Heart3D Fusion Imaging, as well as the granting of a U.S. patent titled “Radial and Trans-endocardial Delivery Catheter.”
Filings also detail capital markets transactions, including private placements of common stock and warrants with institutional investors and certain directors and executive officers, along with related registration rights agreements. These documents explain the structure of the securities, intended use of proceeds for general corporate purposes, and the company’s reliance on exemptions from registration under the Securities Act of 1933.
On Stock Titan, users can review these SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, such as the nature of reported clinical events, terms of financing transactions, or the significance of new patents and partnerships. Real-time updates from the EDGAR system help ensure that new 8-Ks and other filings appear promptly, while tools for viewing transactions related to warrants and other securities tied to BCDAW make it easier to interpret the regulatory record connected to BioCardia’s business.